NEUROPATHOLOGY AND TARGETED MOLECULAR TESTING CORE

$522,275P50FY2014AGNIH

University Of Washington, Seattle WA

Investigators

Linked publications, trials & patents

Paper 39677464 Paper 39666240 Paper 39444005 Paper 39402379 Paper 39402332 Paper 39379761 Paper 39371140 Paper 39345521 Paper 39254167 Paper 39234651 Paper 39231932 Paper 39207439 Paper 39173101 Paper 38980643 Paper 38958543 Paper 38958117 Paper 38949538 Paper 38942763 Paper 38903124 Paper 38883718 Paper 38848188 Paper 38747387 Paper 38721926 Paper 38712163 Paper 38641585 Paper 38460116 Paper 38441951 Paper 38425303 Paper 38423160 Paper 38418871 Paper 38244935 Paper 38244079 Paper 38215191 Paper 38194584 Paper 38014121 Paper 37762325 Paper 37745545 Paper 37606973 Paper 37605362 Paper 37592813 Paper 37580727 Paper 37578203 Paper 37563872 Paper 37547016 Paper 37528055 Paper 37491248 Paper 37338127 Paper 37322115 Paper 37292975 Paper 37292694 Paper 37260021 Paper 37248328 Paper 37245492 Paper 37212114 Paper 37141452 Paper 37125552 Paper 37057867 Paper 37051669 Paper 37038809 Paper 36997127 Paper 36970907 Paper 36946449 Paper 36840665 Paper 36758620 Paper 36722399 Paper 36710669 Paper 36692179 Paper 36681388 Paper 36648159 Paper 36641671 Paper 36628434 Paper 36621368 Paper 36617779 Paper 36577280 Paper 36565204 Paper 36564192 Paper 36530083 Paper 36524738 Paper 36482861 Paper 36453775 Paper 36450991 Paper 36394443 Paper 36324086 Paper 36314203 Paper 36308307 Paper 36289000 Trial NCT02462161 Trial NCT01547169 Trial NCT00161473 Patent 7371731 Patent 7148001 Patent 7094580 Patent 7029710 Patent 6939570 Patent 6767898 Patent 6607758 Patent 6346280 Patent 6264994 Patent 6037327 Patent 5449604

Abstract

The Pacific Northwest Dementia and Aging (PANDA) Neuropathology (NP) Group is a successful cooperative effort between the Alzheimer's Disease (AD) Center at Oregon Health & Science University (OHSU) and the AD Research Center (ADRC) at the University of Washington (UW) that was initiated in July 2003. The initial four Specific Aims of the PANDA NP Group are unchanged from our previous applications: (i) provide diagnostic expertise, (ii) facilitate research, (iii) teach and mentor trainees, and (iv) develop innovative approaches. Two new Specific Aims have been added in this application that are focused on Targeted Molecular Testing (TMT): (v) quantify targeted cerebrospinal fluid (CSF) biomarkers in the UW ADRC CSF Bank that derives in large part from the OHSU ADC and UW ADRC Clinical Cores, and (vi) provide targeted genetic testing relevant to AD and related neurodegenerative diseases. All of our activities are focused on enhancing the research value of tissue and body fluid donations from cognitively healthy individuals and patients with neurodegenerative diseases while insuring proper safeguards.

View original record on NIH RePORTER →